Weight Loss Drugs: New Treatment Strategies for MASLD and MASH

The growing use of weight-loss and obesity medications is showing promise as a potential treatment strategy for metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, metabolic dysfunction-associated steatohepatitis (MASH), according to recent clinical research highlighted in AJMC.

MASLD, formerly known as non-alcoholic fatty liver disease (NAFLD), affects a significant portion of the global population and is closely linked to obesity, type 2 diabetes, and metabolic syndrome. When inflammation and liver cell damage occur alongside fat accumulation, the condition progresses to MASH, which can lead to fibrosis, cirrhosis, and liver failure if left untreated.

Recent clinical trials, including the LEAN study, have demonstrated that glucagon-like peptide-1 (GLP-1) receptor agonists such as liraglutide can produce histological improvements in patients with MASH, including resolution of steatohepatitis in some cases. These findings suggest that medications developed for weight management and glycemic control may have direct benefits on liver pathology beyond weight reduction alone.

Research published in March 2026 in Current Diabetes Reports confirms that resmetirom and semaglutide are currently the only pharmacologic agents specifically approved for the treatment of MASLD. Resmetirom, a thyroid hormone receptor-beta agonist, targets liver fat metabolism directly, while semaglutide, a GLP-1 receptor agonist, addresses multiple metabolic pathways involved in disease progression.

An expanding pipeline of investigational therapies includes dual agonists targeting glucagon and GLP-1 receptors, as well as triple agonists acting on glucose-dependent insulinotropic polypeptide (GIP), GLP-1, and glucagon receptors. These multi-receptor approaches aim to simultaneously regulate appetite, glucose homeostasis, lipid metabolism, and liver inflammation — key factors in the pathogenesis of MASLD and MASH.

A comprehensive review published in Annals of Medicine in December 2024 analyzed research advancements in MASLD/MASH diagnosis and treatment over the past two decades. The study emphasized the role of emerging technologies such as non-invasive imaging and biomarker panels, alongside diversified treatment strategies combining lifestyle intervention, pharmacotherapy, and, in advanced cases, metabolic surgery.

Experts note that while weight loss remains a cornerstone of MASLD management, achieving and sustaining significant reduction through lifestyle changes alone is often challenging. Pharmacologic agents that promote weight reduction and improve metabolic parameters may therefore offer a valuable adjunct, particularly for patients with obesity or type 2 diabetes who are at highest risk for liver disease progression.

Ongoing research continues to evaluate the long-term safety, durability of response, and potential role of combination therapies in preventing cirrhosis and hepatocellular carcinoma in high-risk populations. As understanding of the liver-metabolism axis deepens, weight-loss and obesity drugs are increasingly viewed not just as tools for weight management, but as integral components of a broader therapeutic approach to MASLD and MASH.